Hao-Jie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hao-Jie Chen has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Huai-Qiang Ju
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
24 shared publications - Zhao-Lei Zeng
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
23 shared publications - Rui-Hua Xu
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
22 shared publications - Hui-Yan Luo
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China
20 shared publications - BaoQing Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
19 shared publications - Chiu-Wing Yeung
Sun Yat-sen University Cancer Center 1 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China
19 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Multilayer Modeling Links Molecular Alterations to Transcriptional Regulatory Remodeling across Human Cancers
Transcriptional regulatory remodeling shapes cancer cell states, yet its relationships with genomic and post-translational alterations remain incompletely understood. Here, we developed TregOmic to infer transcriptional regulator activity and integrate it with pan-cancer multi-omics profiles. Across cancer types, aggressive tumor states were associated with reduced lineage-associated activity and increased activity of epithelial-mesenchymal transition (EMT)-related regulators. Copy-number alterations were associated with lineage-associated regulator activity, while several established cancer drivers ranked among mutated genes associated with the largest numbers of regulator activities after covariate adjustment. Phosphosite measurements provided additional information about activity beyond protein abundance. Joint modeling identified distinct combinations of cis- and trans-acting mutations, protein abundance and site-specific phosphorylation associated with regulator activity across cancer contexts. RUNX2 activity was associated with tumor stage and EMT, while RUNX2-pS28 was recurrently associated with RUNX2 activity and showed elevated abundance in multiple tumor cohorts. Together, these findings connect cancer-associated regulatory states to specific molecular alterations and provide a framework for prioritizing candidate regulatory events for functional investigation.
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultilayer Modeling Links Molecular Alterations to Transcriptional Regulatory Remodeling across Human Cancers
Transcriptional regulatory remodeling shapes cancer cell states, yet its relationships with genomic and post-translational alterations remain incompletely understood. Here, we developed TregOmic to infer transcriptional regulator activity and integrate it with pan-cancer multi-omics profiles. Across cancer types, aggressive tumor states were associated with reduced lineage-associated activity and increased activity of epithelial-mesenchymal transition (EMT)-related regulators. Copy-number alterations were associated with lineage-associated regulator activity, while several established cancer drivers ranked among mutated genes associated with the largest numbers of regulator activities after covariate adjustment. Phosphosite measurements provided additional information about activity beyond protein abundance. Joint modeling identified distinct combinations of cis- and trans-acting mutations, protein abundance and site-specific phosphorylation associated with regulator activity across cancer contexts. RUNX2 activity was associated with tumor stage and EMT, while RUNX2-pS28 was recurrently associated with RUNX2 activity and showed elevated abundance in multiple tumor cohorts. Together, these findings connect cancer-associated regulatory states to specific molecular alterations and provide a framework for prioritizing candidate regulatory events for functional investigation.
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
PLA1A Inhibition Enhances Chemoimmunotherapy Efficacy by Blocking Immunosuppressive Macrophage Polarization in Colorectal Cancer
Clinical outcomes are often suboptimal in patients with colorectal cancer treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunologic landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. In this study, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing (scRNA-seq), revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC nonresponders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacologic inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing LysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy. Significance: Chemotherapy-resistant colorectal cancer elevates PLA1A to induce anti-inflammatory macrophage polarization, supporting the potential of PLA1A as a therapeutic target for enhancing chemoimmunotherapy efficacy and as a biomarker of treatment response.
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
PLA1A Inhibition Enhances Chemoimmunotherapy Efficacy by Blocking Immunosuppressive Macrophage Polarization in Colorectal Cancer
Clinical outcomes are often suboptimal in patients with colorectal cancer treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunologic landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. In this study, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing (scRNA-seq), revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC nonresponders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacologic inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing LysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy. Significance: Chemotherapy-resistant colorectal cancer elevates PLA1A to induce anti-inflammatory macrophage polarization, supporting the potential of PLA1A as a therapeutic target for enhancing chemoimmunotherapy efficacy and as a biomarker of treatment response.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S7 Dynamic metabolite model construction and performance evaluation
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S7 Dynamic metabolite model construction and performance evaluation
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S5 Identification of optimal long PFS cutoff to distinguish long and short term responders and key metabolite differences and predictive performance of on-treatment model
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S5 Identification of optimal long PFS cutoff to distinguish long and short term responders and key metabolite differences and predictive performance of on-treatment model
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S3 Baseline metabolite model performance validation and clinical prognostic analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S3 Baseline metabolite model performance validation and clinical prognostic analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S2 Metabolic block construction and validation analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S2 Metabolic block construction and validation analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S4 TG pattern shifts from baseline to on-treatment
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S4 TG pattern shifts from baseline to on-treatment
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to chemoimmunotherapy, with only a minority achieving durable benefit, necessitating dynamic precision monitoring. Through longitudinal plasma metabolomics of 541 serial samples from 252 ESCORT-1st trial patients receiving chemoimmunotherapy plus 3 independent cohorts of 288 samples, we established an integrated risk assessment framework spanning the entire therapeutic continuum: (i) a baseline predictor for initial responders based on metabolite signatures; (ii) an on-treatment predictor in prognosticating long-term responders among initial ones based on treatment-induced metabolic shift patterns; and (iii) a real-time model based on dual alteration of sphingolipid and glycerophospholipid dynamically stratifying progression risk. Meanwhile, 2 dietary metabolites, garlic-derived S-allyl-L-cysteine and cruciferous vegetable–derived indole-3-carbinol, were confirmed to improve outcomes by promoting NK-cell infiltration and reversing CD8+ T-cell exhaustion. In conclusion, we provide the first metabolomic roadmap for precision chemoimmunotherapy in ESCC, unifying baseline prediction, longitudinal surveillance, and dietary modulation into a clinically actionable paradigm.Significance:We established a large-scale plasma metabolomic database from patients with ESCC undergoing chemoimmunotherapy, defining the first noninvasive, comprehensive, and precise monitoring framework for treatment response prediction and risk assessment. Our findings reveal clinically actionable dietary metabolites that may serve as readily accessible adjuvants to enhance chemoimmunotherapy efficacy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to chemoimmunotherapy, with only a minority achieving durable benefit, necessitating dynamic precision monitoring. Through longitudinal plasma metabolomics of 541 serial samples from 252 ESCORT-1st trial patients receiving chemoimmunotherapy plus 3 independent cohorts of 288 samples, we established an integrated risk assessment framework spanning the entire therapeutic continuum: (i) a baseline predictor for initial responders based on metabolite signatures; (ii) an on-treatment predictor in prognosticating long-term responders among initial ones based on treatment-induced metabolic shift patterns; and (iii) a real-time model based on dual alteration of sphingolipid and glycerophospholipid dynamically stratifying progression risk. Meanwhile, 2 dietary metabolites, garlic-derived S-allyl-L-cysteine and cruciferous vegetable–derived indole-3-carbinol, were confirmed to improve outcomes by promoting NK-cell infiltration and reversing CD8+ T-cell exhaustion. In conclusion, we provide the first metabolomic roadmap for precision chemoimmunotherapy in ESCC, unifying baseline prediction, longitudinal surveillance, and dietary modulation into a clinically actionable paradigm.Significance:We established a large-scale plasma metabolomic database from patients with ESCC undergoing chemoimmunotherapy, defining the first noninvasive, comprehensive, and precise monitoring framework for treatment response prediction and risk assessment. Our findings reveal clinically actionable dietary metabolites that may serve as readily accessible adjuvants to enhance chemoimmunotherapy efficacy.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 6: Prediction Result of On-Treatment Metabolite Model for Long-Term Responder
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 6: Prediction Result of On-Treatment Metabolite Model for Long-Term Responder
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S6 Time-dependent metabolic risk analysis and lipid subtype characterization
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S6 Time-dependent metabolic risk analysis and lipid subtype characterization